ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 025

Patient- and Center-level Risk Factors for Research Lost to Follow-up Using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

Monica Aswani, Livie Huie, Kristine Hearld, Melissa Mannion and Emily Smitherman, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Disparities, Pediatric rheumatology, registry

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, March 30, 2023

Title: Poster Breakout 3 - Pediatric Rheumatology Potpourri

Session Type: Breakout Session

Session Time: 5:10PM-5:40PM

Background/Purpose: Clinical registries are typically envisioned to be representative of a target patient population and reflective of health care delivery practices for said population. Variation in clinical practices by different sites and concerns related to recruitment/retention can have profound implications for the validity of data collected and extent to which it may be impacted by selection bias. Thus, the objective of this study is to assess the role of patient- and site-level factors associated with research attrition in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.

Methods: Patients enrolled in the CARRA Registry from 2015 to 2019 were eligible. The effects of patient (level 1) and site (level 2) factors on lost to follow-up were assessed using a 2-level logistic model, followed by empirical Bayes estimation to investigate cross-center variation. Sites classify patients as inactive if they are referred elsewhere, move to a non-CARRA site, transition to adult rheumatology, achieve remission, or are lost to follow-up. We defined our outcome of interest as patients lost to follow-up (= 1) versus all other patients (=0), who may be active or inactive due to other reasons. The empirical Bayes estimates are used to graphically illustrate variation in lost to follow-up rates between unadjusted and adjusted models (Figure 1).

Results: The final analytic sample contained 9,730 patients nested within 69 sites (Table 1). Most of the sample was female (n=6,481, 72%), White (n=6,403, 64%), and privately insured (n=5,559, 62%). Overall, 728 (7.5%) patients in the cohort were lost to follow-up. The intra-class correlation coefficient (ICC) from null model signified that 20.3% of the variance in lost to follow-up is at the registry site level. Percent of missed Registry visits (OR 1.09, 95% CI: 1.086, 1.12), non-Medicaid state insurance (OR 1.95, 95% CI: 1.15, 3.12), and an income between $25,000 and $49,999 (OR 1.52, 95% CI: 1.003, 2.31) were significantly associated with higher odds of lost to follow-up (Figure 2).

Conclusion: Significant variation in research participant lost to follow-up exists at the site level. Moreover, individual-level characteristics such as visit history, insurance status, and household socioeconomic status were associated with the likelihood of being lost to follow-up. This non-random attrition may also highlight concerns related to patient retention in clinical practice.

Supporting image 1Table 1: Descriptive Statistics (N = 9730)

Supporting image 2Figure 1: Site-level Variation. Sites with a negative difference (i.e., higher unadjusted predicted probability, to the left of zero) means controlling for patient- and site-level factors made their lost to follow-up look more favorable. Sites with a positive difference (i.e., higher adjusted predicted probability, to the right of zero) means controlling for patient- and site-level factors made their lost to follow-up look worse off.

Supporting image 3Figure 2: Multilevel Logistic Regression. Reference categories include: Male, White race, private insurance, less than high school, non-PR-COIN site, and site started CARRA enrollment in 2015.


Disclosures: M. Aswani: None; L. Huie: None; K. Hearld: None; M. Mannion: None; E. Smitherman: None.

To cite this abstract in AMA style:

Aswani M, Huie L, Hearld K, Mannion M, Smitherman E. Patient- and Center-level Risk Factors for Research Lost to Follow-up Using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/patient-and-center-level-risk-factors-for-research-lost-to-follow-up-using-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-and-center-level-risk-factors-for-research-lost-to-follow-up-using-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology